Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

October 31, 2013

Conditions
Cervical CancerEndometrial CancerOvarian CancerVaginal CancerCarcinoma of the Vulva
Interventions
DRUG

Avastin

Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Lowell General Hospital

OTHER

collaborator

Saint Anne's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00545792 - Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | Biotech Hunter | Biotech Hunter